Market News AIOpen the app

Canada has approved Lipocine's TLANDO, making it easier for people to get testosterone treatment there.

TrialRead the original at Benzinga
Good for LPCN

Lipocine's TLANDO capsules won Canadian approval, opening a path into a market with many testosterone-replacement prescriptions. Verity holds the sales rights and plans a launch by the end of 2026, so sales are not immediate.

LPCN · Lipocine Inc.

AI read · Good for LPCN

The AI's read

The approval gives TLANDO a path into a country where doctors already write many testosterone-replacement prescriptions. Verity holds the sales rights and is still planning the launch for the end of 2026, so Canadian sales are not immediate. The approval is a step forward for Lipocine, despite the wait.

Get alerts for LPCN

Follow Lipocine Inc. (LPCN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LPCN
Free on the App Store and Google Play, or on the web.